73 patents currently held

56 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2029. from the record

Of the 56 now held by other companies, 28 name Lyft Inc. as their current owner, and 28 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Nov 2029

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026202720282029203020312032203320342035 2036 2037 2038 2039 2040 2041 2042 204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Methods for Isolating, Culturing, and Genetically Engineering Immune Cell Populations for Adoptive Therapy US 11,400,115

The most cited patent in this portfolio, cited by 59 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2037.

Ends Aug 2037 · High confidence Also notable

Engineered Cells for Adoptive Cell Therapy US 10,738,278

Cited by 34 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036.

Ends Apr 2036 · High confidence Also notable

Articles of Manufacture and Methods for Treatment Using Adoptive Cell Therapy US 11,413,310

Cited by 14 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2039.

Ends Feb 2039 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 30, 2027
The maintenance fee for Modified Hepatitis Post-Transcriptional Regulatory Elements (US 10,363,269) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
1 fee due Feb 28, 2027
The maintenance fee for Articles of Manufacture and Methods Related to Toxicity Associated with Cell Therapy (US 11,740,231) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
4 fees due Apr 1 to 30, 2027 · next Apr 1
3 fees due May 14 to 28, 2027 · next May 14
3 fees due Jun 17 to 26, 2027 · next Jun 17
2 fees due Jul 9 to 14, 2027 · next Jul 9
2 fees due Aug 6 to 13, 2027 · next Aug 6
1 fee due Sep 5, 2027
The maintenance fee for Antibodies and Chimeric Antigen Receptors Specific for ROR1 (US 11,919,970) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
1 fee due Oct 2, 2027
The maintenance fee for Articles of Manufacture and Methods for Treatment Using Adoptive Cell Therapy (US 11,944,647) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

3 of the patents on this record were granted since Aug 16, 2026
1 term has ended since Aug 16, 2026

What they patent

The 5 largest of its 55 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Articles of Manufacture and Methods for Treatment Using Adoptive Cell Therapy	3 in force	to Feb 2039
Methods for Isolating, Culturing, and Genetically Engineering Immune Cell Populations for Adoptive Therapy	3 in force	to Aug 2037
Antibodies and Chimeric Antigen Receptors Specific for CD19	3 in force	to Apr 2037
Methods for Producing Genetically Engineered Cell Compositions and Related Compositions	2 in force	to Feb 2041
Method of Assessing Activity of Recombinant Antigen Receptors	2 in force	to Sep 2040

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,455,437	Method to predict and prevent oxygen-induced inflammatory tissue injury held by Juno Therapeutics, Inc. In force Term ends Nov 2, 2029 · High confidence	In force	Term ends Nov 2, 2029	High confidence
US 12,208,137	Methods for Isolating, Culturing, and Genetically Engineering Immune Cell Populations for Adoptive Therapy held by Juno Therapeutics, Inc. In force Term ends Apr 23, 2035 · High confidence	In force	Term ends Apr 23, 2035	High confidence
US 12,296,010	Methods for Isolating, Culturing, and Genetically Engineering Immune Cell Populations for Adoptive Therapy held by Juno Therapeutics, Inc. In force Term ends Apr 23, 2035 · High confidence	In force	Term ends Apr 23, 2035	High confidence
US 11,274,278	Methods, Kits and Apparatus for Expanding a Population of Cells held by Juno Therapeutics, Inc. In force Term ends Apr 28, 2035 · High confidence	In force	Term ends Apr 28, 2035	High confidence
US 10,786,533	Engineered Cells for Adoptive Cell Therapy held by Juno Therapeutics, Inc. In force Term ends Jul 15, 2035 · Medium confidence	In force	Term ends Jul 15, 2035	Medium confidence
US 10,889,652	Antibodies and Chimeric Antigen Receptors Specific for ROR1 held by Juno Therapeutics, Inc. In force Term ends Feb 13, 2036 · High confidence	In force	Term ends Feb 13, 2036	High confidence
US 10,738,278	Engineered Cells for Adoptive Cell Therapy held by Juno Therapeutics, Inc. In force Term ends Apr 15, 2036 · High confidence	In force	Term ends Apr 15, 2036	High confidence
US 10,363,269	Modified Hepatitis Post-Transcriptional Regulatory Elements held by Juno Therapeutics, Inc. In force Term ends Oct 14, 2036 · High confidence	In force	Term ends Oct 14, 2036	High confidence
US 12,129,477	Methods, Kits, Agents and Apparatuses for Transduction held by Juno Therapeutics, Inc. In force Term ends Oct 20, 2036 · Medium confidence	In force	Term ends Oct 20, 2036	Medium confidence
US 11,266,739	Methods and Compositions for Adoptive Cell Therapy held by Juno Therapeutics, Inc. In force Term ends Nov 2, 2036 · High confidence	In force	Term ends Nov 2, 2036	High confidence

10 of 73 patents shown.

Pro members see all 73.

Pro members: see all 73 patents

Also on record, not counted in the 73: 56 patents in force now held by others · 5 patents ended · 99 applications pending · 60 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Juno, Inc.